ew drugs are moving more quickly to market today compared with those launched during the height of the Great Recession, but the pipeline is no faster than it was two decades ago.
That’s a key finding of a new report, released jointly by QuintilesIMS Institute and STAT, that illustrates shifting forces that have high stakes for drug innovation and pricing. The report, which analyzed the lifespans of 667 new drugs launched in the United States over the past two decades, was prepared independently by the QuintilesIMS Institute, in consultation with STAT.
The IMS report raises questions about why the pace of drug development has, overall, been stagnant since the 1990s, with the average drug taking 12 years to be launched after its original patent was filed. That matters because the speed of getting medications to market dictates when patients can be helped — and when companies can get a return on their investment.
“I was surprised that we’re still looking at this average of 12 years,” said Murray Aitken, executive director of QuintilesIMS Institute, who led the preparation of the report.
You can read the full story on STAT Plus.